|View printer-friendly version|
|BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma|
- Omega Pharma to develop and commercialize novel skin treatment
for OTC use in
- First product expected to reach the market in 2016 -
Under the terms of the agreement, Omega Pharma will be responsible for all development activities required to obtain regulatory approval in the licensed territory for at least two OTC indications. In addition, Omega Pharma will sponsor and manufacture the product in the relevant regions, and will have exclusive responsibility for commercialization.
The specific financial terms of the licensing agreement were not disclosed. Omega Pharma will pay BioLineRx an undisclosed amount for each unit sold and BioLineRx will be entitled to certain commercial milestone payments. In addition, BioLineRx will have full access to all clinical and R&D data generated during the performance of the development plan and may use these data in order to develop and/or license the product in other territories and fields of use where it retains the rights.
“We are very pleased to partner with Omega Pharma, a top consumer
healthcare company and a leading provider of over-the-counter medicines
and healthcare products,” stated
Dr. Savitsky concluded, “While our strategic focus remains on advancing
our lead clinical programs in oncology and inflammation, we believe this
partnership, as well as our recent multi-year collaboration with
BL-5010 is a novel product for the non-surgical removal of benign skin
lesions. It offers an alternative to painful, invasive and expensive
removal treatments including cryotherapy, laser treatment and surgery.
Because the treatment is non-invasive, it poses minimal infection risk
and eliminates the need for anesthesia or bandaging. The product has
completed a phase 1/2 pilot clinical study for the removal of seborrheic
keratosis, which showed excellent efficacy and cosmetic results, and has
received confirmation in
About Omega Pharma
Omega Pharma is an OTC healthcare company headquartered in
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a
For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.
Various statements in this release concerning BioLineRx’s future
expectations, including specifically those related to the development
and commercialization of BL-5010, constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements include words such as “may,”
“expects,” “anticipates,” “believes,” and “intends,” and describe
opinions about future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of BioLineRx to be materially
different from any future results, performance or achievements expressed
or implied by such forward-looking statements. Some of these risks are:
changes in relationships with collaborators; the impact of competitive
products and technological changes; risks relating to the development of
new products; and the ability to implement technological improvements.
These and other factors are more fully discussed in the “Risk Factors”
section of BioLineRx’s most recent annual report on Form 20-F filed with